Powering the Immune System to Transform Lives

Our Platforms

Proven Immunologic Prowess, Track Record of Success

Vir has a track record of translating scientific ideas into transformative medicines to benefit people around the world. Our powerful R&D engine is propelled by combining our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant unmet patient need.

our antibody

Proprietary Antibody Platform

Our world class, proprietary monoclonal antibody (mAb) discovery platform is a core strength upon which we continue to build and improve. Leveraging this platform, we are able to identify rare and broad antibodies with enhanced selectivity and potency using artificial intelligence-led (AI) protein engineering.

our Antibody platform

our t cell

T Cell-Based Viral Vector Platform

Our unique T cell based viral vector platform, which is currently being used to develop a vaccine for HIV, has the potential to be more broadly applicable to infectious disease, oncology and beyond.

our T Cell Platform